Approved for use through 9031 2007, Olds 008 1003 U.S. Patient and Trademark Office U.S. DEPARTMENT OF U.S. Patient and Trademark Office U.S. DEPARTMENT OF U.S. Patient and Trademark Office U.S. DEPARTMENT OF U.S. DEPARTMENT OF U.S. Patient and Trademark Office U.S. DEPARTMENT OF U.S. DEPARTMENT O

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	532552000701
In re Application of: Lawrence MAYER et al.	
Application No.: 10/551,579	
Filed: April 2, 2004 (Int'l)	
For: COMBINATION COMPOSITIONS OF CAMPTOTHECINS AND FLUOROPYRIMIDINES	
The owner, Celator Pharmaceuticals, Inc., of 100 person interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the Instant application which would ostend beyond the expiration date of the Util statutory form of any	
patent granted on pending reference Application Numbers 10/817/726 filed 04/02/04/11/304,328 filed 12/14/05, and 105553,373 filed 03/22/07 as such term is defined in \$20 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hency agrees that any patent or granted on the instant applications are commonly owned. This agreement runs with any patent granted on the instant application are commonly owned. This agreement runs with any patent granted on the instant application and is furthed post to residence, its accessors or easigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patient granted on the instant application that would extend to the expiration date of the full statutory stima sedimed in 53 U.S. C.15 and 175 of any patient application, as the expiration date of the full statutory term as defined in 53 U.S. C.15 and 175 of any patient yet reminal disclaimer filled prior to the grant of any patient on the perfull greference application; in the event that: any such patient; granted on the perful greference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a count of competing industries, in statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reliseued, or is in any manner terminated prior to the expiration of its full statutory em as stortened by any terminal disclaimer filled prior to its grant.	
Further, the owner does not disclaim any right to an extension of the term of any patent issuing from the instant application under SS U.S. C.§ \$15.5 for anglusament or plassent to 9.5 U.S. C.§ \$1.54(t) or pursuant to any other subsequently enacted public law or act which provides for extension of term of a patent.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and helief are believed to be true; and further that these statements were made with the knowledge that willful false statements and he like so made are punishable by fine or imprisoment, or both, under Section 1001 of Tills 180 ribe United States Code and that such willful false statements and jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an attorney or agent of record. Reg. No. 29,959	
/Kate H. Murashige/	February 25, 2008
Signature	Date
Kate H. Murashige	
Typed or printed name (858) 720-5112	
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
100	
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	